EU orphan designation for pulmonary arterial hypertension drug
Drug Discovery World
SEPTEMBER 4, 2024
The European Commission has granted orphan medicinal product designation (OMPD) to Cereno Scientific’s lead drug candidate CS1 for pulmonary arterial hypertension (PAH). CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed to offer improved quality of life and prolonged life for patients with PAH. Companies that obtain orphan designation benefit from protocol assistance, a type of scientific advice specific for designated orphan drugs, and market exclusivity once th
Let's personalize your content